Search results for "PC"

showing 10 items of 2805 documents

Influence of prenatal exposure to environmental pollutants on human cord blood levels of glutamate

2013

El pdf del artículo es la versión post-print.

medicine.medical_specialtyPlacentaGlutamic AcidTransport010501 environmental sciencesToxicologyPolychlorobiphenyl (PCB)01 natural sciencesUmbilical cord03 medical and health scienceschemistry.chemical_compoundGlutamatergicGlutamate Plasma Membrane Transport Proteins0302 clinical medicinePregnancyPlacentaInternal medicinemedicineHydrocarbons ChlorinatedHumansMethylmercury0105 earth and related environmental scienceschemistry.chemical_classificationChemistryGeneral NeuroscienceGlutamate receptorMethylmercuryHexachlorobenzeneMercuryFetal Blood3. Good healthAmino acidmedicine.anatomical_structureEndocrinologyBiochemistryExcitatory Amino Acid Transporter 213. Climate actionMaternal ExposureCord bloodOrganochlorine pesticidesEnvironmental PollutantsFemaleGlutamate030217 neurology & neurosurgery
researchProduct

Prognostic Factors for Surgical Failure in Malignant Bowel Obstruction and Peritoneal Carcinomatosis

2021

Introduction: Patients with peritoneal metastasis frequently develop malignant bowel obstruction (MBO). Medical palliative management is preferred but often fails. Conversely, the role of palliative surgery remains unclear and debated. This study aims to identify patients who could benefit from invasive surgical interventions and factors associated with successful surgical palliation.Materials and Methods: In this retrospective study, 98 consecutive patients who underwent palliative surgery for MBO over 5 years were reviewed. We evaluate as the primary outcome surgical failure to select patients who could benefit from palliative surgery, avoiding unnecessary surgery. A prognostic score was …

medicine.medical_specialtyRD1-811business.industrypalliative outcomesmalignant bowel obstruction (MBO)ileostomymedicine.diseaseSurgical failurePeritoneal carcinomatosisSurgeryBowel obstructionSettore MED/40 - GINECOLOGIA E OSTETRICIAperitoneal carcinomatosis (PC)MedicineSurgerybusinesssurgical palliationOriginal ResearchFrontiers in Surgery
researchProduct

Variations of OCT measurements corrected for the magnification effect according to axial length and refractive error in children

2018

Purpose: The aim of this paper was to examine the distribution of macular, retinal nerve fiber layer (RNFL) thickness and optic disc parameters of myopic and hyperopic eyes in comparison with emmetropic control eyes and to investigate their variation according to axial length (AL) and spherical equivalent (SE) in healthy children. Methods: This study included 293 pairs of eyes of 293 children (145 boys and 148 girls), ranging in age from 6 to 17 years. Subjects were divided according to SE in control (emmetropia, 99 children), myopia (100 children) and hyperopia (94 children) groups and according to axial AL in 68 short ([Formula: see text]22.00[Formula: see text]mm, 68), medium (from [For…

medicine.medical_specialtyRefractive errorgenetic structuresmagnification effectBiomedical EngineeringNerve fiber layerMedicine (miscellaneous)MagnificationEmmetropiaUlls -- Acomodació i refraccióSpherical equivalent:Ciències de la visió::Optometria::Acomodació i refracció [Àrees temàtiques de la UPC]lcsh:TechnologyEye--Accommodation and refractionLength measurement03 medical and health sciencesAxial length0302 clinical medicinechildrenOphthalmologyDegeneració retinalmedicinelcsh:QC350-467refractive errorRetinal degenerationOptical coherence tomographybusiness.industrylcsh:TMean ageAxial lengthmedicine.diseaseAtomic and Molecular Physics and Opticseye diseasesElectronic Optical and Magnetic Materialsmedicine.anatomical_structureCoherència (Òptica)OCT measurements030221 ophthalmology & optometryOptometrysense organsbusinessInfants030217 neurology & neurosurgerylcsh:Optics. LightOptic disc
researchProduct

EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study

2021

Abstract Aims To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. Methods and results An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis…

medicine.medical_specialtyRegistryStatinEpidemiologymedicine.drug_class030204 cardiovascular system & hematologyGuidelinesSecondary care03 medical and health sciences0302 clinical medicineEzetimibeRisk FactorsInternal medicinemedicineHumans030212 general & internal medicinePCSK9 InhibitorsDyslipidemiasSecondary preventionPrimary Health Carebusiness.industryAnticholesteremic AgentsStatinsCholesterol LDLGuidelineLipidsConfidence intervalCross-Sectional StudiesTreatment OutcomeCholesterolCardiovascular DiseasesObservational studyHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugDA VINCI study
researchProduct

Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?

2017

Abstract According to current European guidelines, lipid lowering therapy for progressive cardiovascular disease including cardiovascular events has to be focused on a target level for LDL-C. In contrast for Lp(a) a threshold has to be defined with respect to the method of measurement. However, due to new lipid lowering drug developments like PCSK9-inhibitors (PCSK-9-I) a therapeutic algorithm for patients with severe hypercholesterolemia or isolated Lipoprotein(a)-hyperlipoproteinemia with progressive cardiovascular disease may be necessary to manage the use of PCSK9-I, lipoprotein apheresis (LA) or both. The therapeutic approach for patients with homozygous familial hypercholesterolemia i…

medicine.medical_specialtySerine Proteinase InhibitorsDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologyRisk AssessmentHyperlipoproteinemia Type II03 medical and health sciencesTherapeutic approach0302 clinical medicineRisk FactorsInternal medicineGermanyInternal MedicinemedicineHumans030212 general & internal medicinePCSK9 Inhibitorsbiologybusiness.industryPCSK9Anticholesteremic AgentsPCSK9 InhibitorsGeneral MedicineLipoprotein(a)Cholesterol LDLmedicine.diseaseCombined Modality TherapyEndocrinologyTreatment OutcomeCardiovascular Diseasesbiology.proteinCardiologyBlood Component Removallipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessLipoprotein apheresisBiomarkersLipoproteinLipoprotein(a)Atherosclerosis. Supplements
researchProduct

Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk

2014

Statins are the first-line therapy in LDL-Cholesterol (LDL-C) reduction and its clinical use has contributed to significant prevention and treatment of atherosclerotic vascular disease. Yet, a significant proportion of patients remain at high risk. Recently, a number of new therapies have been developed to further lower LDL-C. These agents may provide clinical benefit on top of statin therapy in patients with high residual risk, severe hypercholesterolemia or as an alternative for patients who are intolerant to statins. We review four novel approaches based on the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein-B100 (apoB), Cholesteryl ester transport pro…

medicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BHypercholesterolemiaMipomersenFamilial hypercholesterolemiaBioinformaticschemistry.chemical_compoundRisk FactorsAnacetrapibInternal medicinemedicineHumansStatins Novel LDL-C lowering drugs Mipomersen Lomitapide Anacetrapib Evacetrapib PCSK9 inhibitorsbiologybusiness.industryAnticholesteremic AgentsPCSK9nutritional and metabolic diseasesLipid Metabolismmedicine.diseaseLomitapideResidual riskEndocrinologychemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessEvacetrapibCurrent Atherosclerosis Reports
researchProduct

ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiova…

2017

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

medicine.medical_specialtySettore MED/09 - Medicina InternaPCSK9 inhibitorMEDLINE030204 cardiovascular system & hematologyNOatherosclerosis; diagnostic and therapeutic pathways; hypercholesterolaemia; PCSK9 inhibitors; statins; sustainable health careDiagnostic and therapeutic pathways03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicine030212 general & internal medicineIntensive care medicineRisk managementCause of deathHypercholesterolaemiabusiness.industryAtherosclerotic cardiovascular diseaseCholesterolSustainable health careStatinsDiagnostic and therapeutic pathwayStatinHigh Cholesterol LevelsArticlesmedicine.diseaseAtherosclerosischemistryPCSK9 inhibitorsAtherosclerosiCardiologylipids (amino acids peptides and proteins)Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal Supplements : Journal of the European Society of Cardiology
researchProduct

The accuracy of calculated base excess in blood.

2002

Most equations used for calculation of the base excess (BE, mmol/l) in human blood are based on the fundamental equation derived by Siggaard-Andersen and called the Van Slyke equation: BE = Z x [[cHCO3-(P) - C7.4 HCO3-(P)] + beta x (pH -7.4)]. In simple approximation, where Z is a constant which depends only on total hemoglobin concentration (cHb, g/dl) in blood, three equations were tested: the ones proposed by Siggaard-Andersen (SA), the National Committee for Clinical Laboratory Standards (NCCLS) or Zander (ZA). They differ only slightly in the solubility factor for carbon dioxide (alphaCO2, mmol/l x mmHg) and in the apparent pK(pK'), but more significantly in the plasma bicarbonate conc…

medicine.medical_specialtySimple equationPartial PressureClinical BiochemistryAnalytical chemistrypCO2HemoglobinsReference ValuesmedicineMethodsHumansSolubilityWhole bloodAcid-Base EquilibriumHuman bloodChemistryBiochemistry (medical)Reproducibility of ResultsGeneral MedicineCarbon DioxideHydrogen-Ion ConcentrationSurgeryOxygenBicarbonatesBloodChemistry ClinicalArterial bloodBase excessAcid–base reactionClinical chemistry and laboratory medicine
researchProduct

Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins

2022

Dyslipidaemia in type 2 diabetes mellitus (T2DM), which increases cardiovascular risk, includes abnormal metabolism of low-density lipoproteins (LDL). Our group has recently shown that liraglutide increases LDL catabolism in patients with T2DM and that it reduces the expression of PCSK9 (a major inhibitor of LDL-receptor expression) in vitro and in mice. This prompted us to study the effect of liraglutide on plasma PCSK9 level in patients with T2DM.We studied prospectively 82 patients with T2DM (51 without statins, 31 with statins). Plasma PCSK9 and plasma lipids were measured before and six months after the initiation of a treatment with liraglutide at a dose of 1.2 mg/day.Plasma PCSK9 was…

medicine.medical_specialtyStatinendocrine system diseasesmedicine.drug_classEndocrinology Diabetes and MetabolismType 2 diabetesMiceEndocrinologyDiabetes mellitusInternal medicineInternal MedicinemedicineAnimalsHumansGlycated HemoglobinCatabolismbusiness.industryLiraglutidePCSK9nutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineMetabolismLiraglutidemedicine.diseaseEndocrinologyDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9businessmedicine.drugDiabetes & Metabolism
researchProduct

Retrograde recanalization of an in-stent ostial chronically occluded right coronary artery

2010

We describe a case of a chronic proximal in-stent CTO extending up to the ostium of a right coronary artery where successful achievement of guidewire passage through the CTO was performed with a retrograde approach. Guidewire trapping into the right guiding catheter was performed thereafter and procedure was completed by retrograde balloon crossing and antegrade stenting. © 2009 Elsevier Ireland Ltd.

medicine.medical_specialtySurgical approachbusiness.industrymedicine.medical_treatmentStentPCIequipment and suppliesBalloonRetrograde approach.SurgeryCTOOstiumsurgical procedures operativeRight coronary arterymedicine.arteryConventional PCIRetrograde approachGuiding catheterMedicinecardiovascular diseasesRadiologyCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct